Dana Investment Advisors Inc. Sells 13,875 Shares of Lantheus Holdings, Inc. $LNTH

Dana Investment Advisors Inc. reduced its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 69.7% during the third quarter, Holdings Channel reports. The fund owned 6,044 shares of the medical equipment provider’s stock after selling 13,875 shares during the period. Dana Investment Advisors Inc.’s holdings in Lantheus were worth $310,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Stanley Laman Group Ltd. lifted its stake in shares of Lantheus by 38.7% in the 3rd quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after acquiring an additional 22,229 shares during the last quarter. American Assets Inc. bought a new position in Lantheus during the 3rd quarter worth approximately $872,000. Campbell & CO Investment Adviser LLC purchased a new position in Lantheus in the 3rd quarter worth approximately $2,184,000. Assetmark Inc. lifted its position in Lantheus by 20.1% in the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock valued at $6,078,000 after purchasing an additional 19,844 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Lantheus during the second quarter valued at approximately $654,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on LNTH shares. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Citizens Jmp raised their price target on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a report on Tuesday. JonesTrading restated a “hold” rating on shares of Lantheus in a research report on Friday. Truist Financial set a $89.00 target price on shares of Lantheus in a report on Friday. Finally, Citigroup reissued an “outperform” rating on shares of Lantheus in a research note on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus price target of $82.17.

Lantheus Stock Down 0.7%

Shares of NASDAQ LNTH opened at $74.91 on Friday. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.29. The firm has a market capitalization of $4.97 billion, a PE ratio of 22.23 and a beta of -0.08. The firm has a fifty day simple moving average of $68.15 and a two-hundred day simple moving average of $60.14.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.37%. The firm had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. During the same quarter in the previous year, the firm posted $1.59 EPS. The company’s revenue for the quarter was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Key Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.